Literature DB >> 23389938

Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency.

Roser Pons1, Dimitris Syrengelas, Sotiris Youroukos, Irene Orfanou, Arqirios Dinopoulos, Bru Cormand, Aida Ormazabal, Angels Garzía-Cazorla, Mercedes Serrano, Rafael Artuch.   

Abstract

The objective of this study was to characterize levodopa (l-dopa)-induced dyskinesias in patients with tyrosine hydroxylase deficiency. Clinical observation was carried out on 6 patients who were diagnosed with tyrosine hydroxylase deficiency and were treated with escalating doses of l-dopa. All 6 patients showed l-dopa-induced dyskinesias of variable intensity early in the course of treatment and regardless of the age of initiation. l-Dopa-induced dyskinesias were precipitated by increases in the dose of l-dopa and also by febrile illnesses and stress. They caused dysfunction and distress in 2 patients. The dyskinesias were improved by decreasing the l-dopa dose or by slowing its titration upward. Increasing the dose frequency was helpful in 2 patients, and introducing amantadine was helpful in another 2 patients. l-Dopa-induced dyskinesias are a common phenomenon in tyrosine hydroxylase deficiency. The current observations show that l-dopa-induced dyskinesias are frequent in a dopamine-deficient state in the absence of nigrostriatal degeneration. Although l-dopa-induced dyskinesias in tyrosine hydroxylase deficiency are phenomenologically similar to those that occur in Parkinson's disease, they are different in a number of other respects, suggesting intrinsic differences in the pathophysiologic basis of l-dopa-induced dyskinesias in the 2 conditions. © 2013 Movement Disorder Society.
Copyright © 2012 Movement Disorder Society.

Entities:  

Keywords:  chorea; dyskinesias; levodopa; tyrosine hydroxylase deficiency

Mesh:

Substances:

Year:  2013        PMID: 23389938     DOI: 10.1002/mds.25382

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

Review 1.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

2.  A Severe l-Dopa Responsive Dystonia With Slow and Continuous Improvement in a Patient With a Novel Mutation in the Tyrosine Hydroxylase Gene.

Authors:  Christian Marques Couto; Antônio Pedro Vargas; Fernando Dos Santos Coimbra; Olimar Leite de Assis Cunha; Lucia Willadino Braga
Journal:  Mov Disord Clin Pract       Date:  2019-05-02

3.  Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.

Authors:  M Y Wong; A Borgkvist; S J Choi; E V Mosharov; N S Bamford; D Sulzer
Journal:  Neuroscience       Date:  2015-01-28       Impact factor: 3.590

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 5.  Synaptic plasticity may underlie l-DOPA induced dyskinesia.

Authors:  Anders Borgkvist; Ori J Lieberman; David Sulzer
Journal:  Curr Opin Neurobiol       Date:  2017-11-07       Impact factor: 6.627

Review 6.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 7.  Dopa-responsive dystonia--clinical and genetic heterogeneity.

Authors:  Subhashie Wijemanne; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

Review 8.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

Review 9.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

10.  Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.

Authors:  Anders Borgkvist; Elizabeth M Avegno; Minerva Y Wong; Mazen A Kheirbek; Mark S Sonders; Rene Hen; David Sulzer
Journal:  Neuron       Date:  2015-09-02       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.